SEC Form 4/A · accession 0001104659-17-074883
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
Michael F. Pehl
Officer — President and CEO · Director
Period of report
Dec 7, 2017
Accepted (ET)
Dec 22, 2017 · 4:39 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy)F4,F1 | $11.86 | Dec 7, 2017 | A | 119,237 | A | — | Dec 7, 2024 | Common Stock, par value $0.01 per share | 119,237 | 119,237 | D |
| Stock Options (right to buy)F4,F2,F3 | $11.86 | Dec 7, 2017 | A | 320,139 | A | — | Dec 7, 2024 | Common Stock, par value $0.01 per share | 320,139 | 320,139 | D |
Explanation of responses
- F1The reporting person was granted stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options vest 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter.
- F2The reporting person was granted performance-based vesting stock options pursuant to the Company's 2014 Long-Term Incentive Plan. The stock options will vest (i) as to 151,678 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant (each date a "Vesting Date") and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $23.72 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date; and (ii) as to 168,461 shares (a) 25% on the first anniversary of the date of grant and 2.08333% on a monthly basis thereafter through the fourth anniversary of the date of grant and (b) subject to Immunomedics, Inc. common stock achieving a fair market value of $35.58 or higher based on the average closing price for the prior 15 consecutive trading days on such Vesting Date.
- F3If the performance-based vesting criteria of the stock options is not attained on an applicable Vesting Date, and to the extent such performance-based vesting criteria is subsequently attained, the applicable tranche of stock options may vest on the date such criteria is met.
- F4The purpose of this amendment is to correct the number of shares reported in Table II, Column 5, Column 7 and Column 9.